Chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL) are types of blood cancer. They develop in types of white blood cells called B cells or T cells, or the precursors to these cells.

Nurix Therapeutics, Inc. (($NRIX)) announced an update on their ongoing clinical study. Nurix Therapeutics, Inc. is conducting a clinical study ...

Jaypirca is a targeted therapy for CLL and other specific cancers. It is known as a Bruton’s tyrosine kinase inhibitor (BTK inhibitor). BTK is an enzyme that helps certain types of cancer cells grow.

BeOne Medicines (($ONC)) announced an update on their ongoing clinical study. Study Overview: The clinical study titled A Phase 1/2, Open-Label, ...

Chemotherapy and Bone Marrow Transplantation for Cancer Patients Who Are Also Chronic Hepatitis B Carriers: A Review of the Problem PURPOSE: To review the recent major advances in the molecular and ...

600 mg once daily bexobrutideg oral dose cleared by global regulators for pivotal monotherapy trials in relapsed/refractory chronic lymphocytic ...

Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) are types of slow-growing cancers that affect a type of white blood cell called a lymphocyte. Lymphocytes are cells that help ...

Open-Source Hybrid Large Language Model Integrated System for Extraction of Breast Cancer Treatment Pathway From Free-Text Clinical Notes The diagnosis of chronic lymphocytic leukemia (CLL) is often ...

B-PLL is a rare subtype that’s more aggressive than other blood cancers and has a low survival rate. However, ongoing research and clinical trials may offer new treatment options to improve outcomes.

The global chronic lymphocytic leukemia therapeutics market is poised for steady expansion, with an expected compound annual growth rate (CAGR) of 7% from 2025 to 2030. Growth is driven by rapid ...